<div id="readability-page-1"><div><p>Artificial intelligence in healthcare is attracting attention as investors weigh inflation risks, higher energy costs, and shifting central bank signals. While input prices and borrowing costs are in focus across regions, AI tools that help hospitals work more efficiently, support telemedicine, and speed up drug discovery are drawing interest from those looking for long term structural themes rather than short term macro swings. This article looks at a curated Transformative AI Healthcare Stocks screener and highlights 3 stocks from it, helping you quickly spot companies tied to AI driven improvements in diagnostics, treatment and research.</p> <h2>GeneDx Holdings (WGS)</h2> <p><strong>Overview:</strong> GeneDx Holdings is a genomics company that provides whole exome and whole genome sequencing for pediatric and rare diseases, using an AI based platform to interpret results for rare disease, hereditary risk, and cancer testing. It also offers data and information services that draw on a large rare disease dataset to support clinicians and biopharma partners.</p> <p><strong>Market Cap:</strong> US$2.02b</p> <p>GeneDx sits at the crossroads of AI and genomics, with an AI based engine that helps clinicians make sense of complex exome and genome data for rare and pediatric conditions, and a growing dataset that biopharma companies can use for drug research. Analysts currently forecast revenue and earnings growth over the coming years; however, the company is still loss making, exposed to reimbursement pressures, elevated operating costs, and a new US$100 million term loan. Recent guidance cuts, insider selling, and volatile trading show how sensitive the stock is to execution. If you are interested in AI driven diagnostics and can tolerate swings in sentiment, this is a business where the long term outcome may depend on key assumptions about growth, margins, and funding.</p> <p>Revenue forecasts, a large rare disease dataset, and a fresh US$100m term loan make GeneDx a high potential but finely balanced story, so pressure test the long term setup with the 3 key rewards and 2 important warning signs (1 is major!)</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/355ae0a7-ce85-4b2e-8d8d-4cd81f3b6290/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/355ae0a7-ce85-4b2e-8d8d-4cd81f3b6290/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTA2"/><figcaption>NasdaqGS:WGS Earnings &amp; Revenue Growth as at May 2026</figcaption></figure> <h2>Medtronic (MDT)</h2> <p><strong>Overview:</strong> Medtronic is a large medical device company that makes pacemakers, heart valves, surgical tools, brain and spine implants, diabetes devices, and monitoring systems that hospitals and clinicians use in everyday care. Its products are used worldwide across cardiology, surgery, neurology, and diabetes management.</p> <p><strong>Operations:</strong> Medtronic generates most of its roughly US$35.5b in annual revenue from Cardiovascular (US$13.5b), Neuroscience (US$10.2b), and Medical Surgical (US$8.6b), with US$3.0b from Diabetes and the balance from smaller segments.</p> <p><strong>Market Cap:</strong> US$100.53b</p> <p>For investors tracking AI in healthcare, Medtronic combines a large installed base of devices with software rich platforms such as its AI powered surgical video tools and Hugo robotic surgery system. This is backed by around US$2.7b a year in R&amp;D. The company offers a 3.65% dividend yield and has grown earnings recently, although growth forecasts are moderate and returns on equity are in single digits, so expectations may need to stay grounded. Recent approvals and acquisitions in electrophysiology and cardiovascular technology illustrate how Medtronic is leaning into data driven and minimally invasive care. However, cybersecurity events, product recalls, and tough competition in diabetes and cardiac care remain key watchpoints for anyone considering the stock as an AI healthcare play.</p> <p>Medtronic’s AI surgery push, US$35.5b revenue base, and 3.65% yield are only part of the story. See how these pieces fit together in the analysis report for Medtronic</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/944efa19-1e76-489e-941a-7fd24fa70fab/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/944efa19-1e76-489e-941a-7fd24fa70fab/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA2"/><figcaption>NYSE:MDT P/E Ratio as at May 2026</figcaption></figure> <h2>Stryker (SYK)</h2> <p><strong>Overview:</strong> Stryker is a large medical technology company that sells surgical tools, AI assisted virtual care platforms, robotic systems like Mako, and implants for hip, knee, shoulder and other joint replacements to hospitals and clinicians worldwide.</p> <p><strong>Operations:</strong> Stryker generates about US$9.5b from Orthopaedics and US$15.8b from MedSurg and Neurotechnology, with most revenue coming from the United States.</p> <p><strong>Market Cap:</strong> US$111.4b</p> <p>Stryker brings together a sizeable orthopaedic implant business, a suite of smart robotics such as Mako, and AI supported hospital platforms like SmartHospital, all backed by double digit historical and forecast earnings growth. At the same time, the stock carries a high P/E, meaningful debt that relies on higher risk funding sources, and a recent cyber incident that disrupted production and shipping even though management has restored operations and kept full year guidance. For investors who want exposure to AI in day to day hospital workflows and are comfortable weighing growth against leverage and valuation, this is a story where the details matter far more than the headlines.</p> <p>Growth, robotics and hospital AI platforms are pulling in attention, but Stryker’s story looks very different once you factor in valuation pressures and debt, so unpack the trade off inside the 4 key rewards and 1 important warning sign</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ed9eaa22-c6de-4730-9360-528080e77a31/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ed9eaa22-c6de-4730-9360-528080e77a31/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA2"/><figcaption>NYSE:SYK P/E Ratio as at May 2026</figcaption></figure> <p>The three stocks covered here are just a sample of the opportunities tied to AI driven diagnostics, personalized care, and smarter hospital workflows, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener uncovered 32 more companies with equally compelling narratives around these themes. Use Simply Wall St to quickly identify and analyze the specific catalysts that matter to you, from AI powered imaging and robotics to genomic data and telemedicine, so you can focus on the ideas you find most compelling within this space.</p> <h2>Take Control of Your Investment Journey</h2> <p> If GeneDx Holdings or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.             Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.             Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.             By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.         </p> <h2>Seeking Fresh Alternatives For Your Curiosity?</h2> <p>Stocks can change quickly, and the strongest ideas often emerge before most investors notice. Scan curated shortlists that are under the radar for now, while it matters, and consider opportunities earlier in their development.</p> <ul> <li>Explore potential income with a curated group of companies in the 13 dividend fortresses that aim to keep cash flowing even when growth stories lose momentum.</li> <li>Review companies in the hand picked list of solid balance sheet and fundamentals (46 results) so you are less likely to be holding fragile businesses if conditions suddenly shift.</li> <li>Look for early movers in AI by scanning a focused set of 64 profitable AI stocks that aren't just burning cash before the broader market fully evaluates their cash generation and operational momentum.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

LABU

IDNA

<p>Artificial intelligence is gaining traction in healthcare, attracting investors amid inflation and energy cost concerns. This article highlights three stocks: GeneDx Holdings, a genomics company utilizing AI for rare disease testing; Medtronic, a medical device giant integrating AI in surgical tools; and Stryker, known for its AI-assisted surgical platforms. Each company presents unique growth opportunities and challenges, including financial pressures and market competition. Investors interested in AI-driven healthcare innovations should consider these stocks while being mindful of their respective risks and market dynamics.</p>

If AI Reshapes Healthcare, These Three Stocks Could Lead